RxDoctor Payments Data

James Rocco, MD

Internal Medicine · Wakefield, MINPI 1710075346

Payments from drug & device makers

$5,293in general payments, 2019–2025

Across 316 payments — averaging $16.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Pfizer$908
  • Bayer$355
  • AbbVie$352
  • Boehringer Ingelheim$337
  • Novartis$301
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$5,272100%
  • Education$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,293 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$216,901
Medicare patients
285
Services billed
1,866

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban583$205,645
OtezlaApremilast18$73,319
XareltoRivaroxaban140$45,724
JardianceEmpagliflozin73$43,343
JanuviaSitagliptin Phosphate62$33,945
XifaxanRifaximin15$23,632
FarxigaDapagliflozin Propanediol26$21,498
Nurtec OdtRimegepant Sulfate12$19,306
Lantus SolostarInsulin Glargine,hum.Rec.Anlog130$18,865
TradjentaLinagliptin38$18,627
Lagevrio (Eua)Molnupiravir20$16,903
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$15,973
Potassium Chloride758$14,959
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog53$14,031
Atorvastatin Calcium781$13,422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$908$224,951595 claims
AmgenOtezla$252$73,31918 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$337$72,225128 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Nexium$1,129$55,128111 claims
MerckJanuvia, Lagevrio (Eua)$61$50,84882 claims
Johnson & JohnsonXarelto$39$45,724140 claims
GSKIncruse Ellipta, Breo Ellipta$13$16,45948 claims
Astellas Pharma US IncMyrbetriq$14$9,28034 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Wakefield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →